VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
PredOmix has developed a novel blood test that can detect about 32 cancers in both men and women with 98 percent accuracy
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
